Executive Summary from Expert consensus on effectiveness and safety of iDPP-4 in the treatment of patients with diabetes and COVID-19

Endocrinol Diabetes Nutr (Engl Ed). 2022 Mar;69(3):209-218. doi: 10.1016/j.endien.2022.02.008. Epub 2022 Feb 18.

Abstract
in English, Spanish

Background: This consensus aims to clarify the role of Dipeptidyl Peptidase-4 inhibitors (iDPP-4) in managing patients with diabetes during the COVID-19 pandemic.

Materials and methods: A PubMed bibliographic search was carried out (December 2019-February 2021). Oxford methodology was used for the evaluation of evidence and possible recommendations were established by consensus.

Results: Diabetes appears to be an independent factor in COVID-19 disease (evidence 2b). No increased risk of contagion with iDPP-4 is demonstrated (evidence 2b), and its use has been shown to be safe (evidence 2b). The use of this drug may present a specific benefit in reducing mortality, particularly in in-hospital use (evidence 2a), reducing admission to intensive care units (evidence 2b) and the need for mechanical ventilation (evidence 2b).

Conclusions: The use of iDPP-4 appears to be safe in patients with COVID-19, and quality studies are needed to clarify their possible advantages further.

Antecedentes: El objetivo de este consenso es esclarecer el papel de los iDPP-4 en el manejo de los pacientes con diabetes durante la pandemia por COVID-19.

Material y métodos: Se llevó a cabo una búsqueda bibliográfica en PubMed (diciembre 2019–febrero de 2021). Se empleó la metodología Oxford y se establecieron de forma consensuada posibles recomendaciones.

Resultados: La diabetes parece ser un factor independiente en la enfermedad de COVID-19 (evidencia 2b). No se demuestra mayor riesgo de contagio con iDPP-4 (evidencia 2b) y su uso ha demostrado ser seguro (evidencia 2b). Los iDPP-4 pueden presentar un cierto beneficio en la reducción de la mortalidad, particularmente su uso intrahospitalario (evidencia 2a), reduciendo la admisión a unidades de cuidados intensivos (evidencia 2b) y la necesidad de ventilación mecánica (evidencia 2b).

Conclusiones: Los iDPP-4 parecen ser fármacos seguros en pacientes con COVID-19 y se necesitan estudios de calidad que aclaren sus posibles ventajas.

Keywords: Antidiabetic drugs; COVID-19; Diabetes; Fármacos antidiabéticos; Mortalidad; Mortality; iDPP-4.

Publication types

  • Practice Guideline

MeSH terms

  • COVID-19*
  • Consensus
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Dipeptidyl-Peptidase IV Inhibitors* / pharmacology
  • Dipeptidyl-Peptidase IV Inhibitors* / therapeutic use
  • Humans
  • Pandemics

Substances

  • Dipeptidyl-Peptidase IV Inhibitors